KRAS and lung adenocarcinoma: In conclusion, our work illustrated the mutation spectrum of EGFR, KRAS, HER2, BRAF and ALK in lung adenocarcinoma, as well as confirmed that hTERT 5′ promoter region mutation rarely occurred in NSCLC samples.